Loading stock data…
ABOS
$2.48+0.10 (+4.20%)
After Hours$2.52+0.04 (+1.61%)· Last close May 4
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acumen Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.49. The stock is currently 31% below its 52-week high of $3.60, remaining 19.7% above its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why ABOS maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.48
Potential Upside
5%
Whystock Fair Value$2.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$202.92M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-172.28%
Volume
Today's trading volume
303,111
Recent News
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Acumen Pharmaceuticals (ABOS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby summary of Acumen Pharmaceuticals, Inc.'s Q4 2025 earnings call
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...
Acumen Pharmaceuticals Inc (ABOS) reports significant clinical progress and strategic partnerships, despite increased R&D expenses and a net loss for 2025.
Acumen Pharmaceuticals Q4 Earnings Call Highlights
Acumen Pharmaceuticals (NASDAQ:ABOS) outlined progress across its lead Alzheimer’s disease program and an emerging “enhanced brain delivery” (EBD) platform during its fourth-quarter and full-year 2025 update, while management reiterated expectations for a key Phase 2 readout later in 2026 and provid